Last reviewed · How we verify
Aflibercept Injection [Eylea]
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their signaling to reduce abnormal blood vessel growth and vascular permeability in the eye. Used for Neovascular (wet) age-related macular degeneration (AMD), Macular edema following retinal vein occlusion (RVO), Diabetic macular edema (DME).
At a glance
| Generic name | Aflibercept Injection [Eylea] |
|---|---|
| Also known as | Eylea injection, Eylea treatment, Intravitreal Aflibercept injection, Intravitreal Eylea injection, Intravitreal anti VEGF injection |
| Sponsor | Caregen Co. Ltd. |
| Drug class | VEGF inhibitor (soluble decoy receptor) |
| Target | VEGF-A, VEGF-B, PlGF (Placental Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their native receptors on endothelial cells, thereby suppressing pathological neovascularization and vascular leakage. This mechanism is particularly effective in retinal diseases characterized by abnormal blood vessel proliferation and increased vascular permeability.
Approved indications
- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Cataract
- Vitreous floaters
- Intraocular pressure elevation
- Endophthalmitis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aflibercept Injection [Eylea] CI brief — competitive landscape report
- Aflibercept Injection [Eylea] updates RSS · CI watch RSS
- Caregen Co. Ltd. portfolio CI